Jiangsu Xikang Technology Co., Ltd. announced that it will receive CNY 140 million in funding from returning investor Shanghai Labway Clinical Laboratory Co., Ltd. on August 24, 2022. The transaction is approved at the eighth meeting of the third board of directors.
Shanghai Labway Clinical Laboratory Co., Ltd
Equities
301060
CNE100004RG8
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 CNY | -3.07% | -1.56% | -24.00% |
1st Jan change | Capi. | |
---|---|---|
-24.00% | 575M | |
-20.70% | 7.83B | |
+0.14% | 2.58B | |
-8.23% | 2.48B | |
-40.47% | 2.46B | |
-14.15% | 1.84B | |
-20.84% | 1.53B | |
-42.17% | 1.22B | |
+16.01% | 1.2B | |
+14.92% | 961M |
- Stock Market
- Equities
- 301060 Stock
- News Shanghai Labway Clinical Laboratory Co., Ltd
- Jiangsu Xikang Technology Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Labway Clinical Laboratory Co., Ltd